Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care
Patients will report taking new diabetes meds during admission histories as more GLP-1 agonists and SGLT2 inhibitors hit the market.
GLP-1 agonists are becoming a crowded group. Once-WEEKLY exenatide (Bydureon BCise) and semaglutide (Ozempic) bring the tally to eight.
Bydureon BCise is extended-release exenatide, like Bydureon. You may hear it gives more consistent drug levels in a simpler pen device.